

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A method for increasing blood platelet formation count in a patient in need of said therapy thereof, comprising administering to said patient an effective amount of a composition comprising for said therapy of, as active ingredient, a parathyroid hormone (PTH) or at least one PTH-a derivative thereof. effective for said therapy, wherein said PTH or PTH derivative is selected from groups (a) to (c):
 - (1) a PTH derivative which comprises PTH(1-34), the constituent amino acid(s) of which may be substituted in the 8-position, 16-position and/or 34-position,
 - (2) a PTH derivative which is such that one or more of the constituent amino acids of PTH(1-34), the constituent amino acid residue(s) of which may be substituted in the 8-position, 16-position and/or 34-position, are deleted, and
 - (3) PTH or a PTH derivative selected from the group consisting of human PTH(1-34), human PTH(1-34)-

~~NH₂, human PTH(1-37), human PTH(1-64), human PTH(1-84), human PTH(35-84) and bovine PTH(1-34).~~

2. (currently amended) The method according to claim 1 wherein said PTH or PTH derivative modified with polyethylene glycol is administered ~~along with polyethylene glycol~~.

3. (original) The method according to claim 1 wherein said PTH or PTH derivative is administered encapsulated within microcapsules.

4. (currently amended) The method according to claim 1 wherein said PTH or PTH derivative is ~~administered in a form incorporated in a sheet of gel.~~

5. (original) The method according to claim 1 wherein said patient is a patient suffering from thrombocytopenia purpura.

6. (currently amended) The method according to claim 1 wherein said patient is ~~one-a patient~~ suffering from selective suppression of megakaryocytes.

7. (original) The method according to claim 6 wherein said patient is a patient who has been or is being

treated with at least one of phenylbutazone, gold compounds, tolbutamide and chemotherapeutics.

8. (currently amended) The method according to claim 1 wherein said patient is ~~one-a patient~~ suffering from a viral infection.

9. (currently amended) The method according to claim 1 wherein said patient is ~~one-a patient~~ suffering from aplastic anemia.

10. (currently amended) The method according to claim 1 wherein said patient is ~~one-a patient~~ suffering from osteomyelodysplasia syndrome.

11. (currently amended) The method according to claim 1 wherein said patient is ~~one-a patient~~ suffering from leukemia.

12. (currently amended) The method according to claim 1 wherein said patient is ~~one-a patient~~ suffering from multiple myeloma.

13. (original) The method of claim 1 wherein said PTH or PTH derivative is selected from the group consisting of human PTH (1-34), human PTH (1-64), human PTH (35-84), bovine

PTH (1-34), human PTH (1-84), human PTH (1-38) and human PTH (1-37).

14. (original) The method of claim 13 wherein said PTH or said PTH derivative has at least one of the following substitutions: (1) substitution of leucine or norleucine at the 8-position, (2) substitution of leucine or norleucine at the 18-position, and (3) substitution to tyrosine at the 34-position.

15. (currently amended) The method according to claim 1 wherein said effective amount is in the range of 1 µg to 1,000 µg per kg of body weight administered systemically at a frequency ranging from once per day to once per month.

16. (currently amended) The method according to claim 1 wherein said effective amount is from 5 µg to 200 µg per kg of body weight administered from once every two weeks to once daily.

17. (original) The method according to claim 1 wherein the route of said administration is subcutaneously.

18. (original) The method according to claim 1 wherein the route of said administration is intravenously.

19. (original) The method according to claim 1
wherein the route of said administration is intranasally.

20. (original) The method according to claim 1
wherein the route of said administration is transpulmonarily.

21. (new) The method of claim 13, wherein said PTH
or PTH derivative is human PTH (1-34).